Bookmark
Forward
QuickView for Trifluridine (compound)
PubChem
| Name: | Trifluridine |
|---|---|
| PubChem Compound ID: | 253083 |
| Description: | An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557) |
| Molecular formula: | C10H11F3N2O5 |
| Molecular weight: | 296.2 g/mol |
| Synonyms: |
Viroptic; NSC75520; 5-Trifluoromethyl-2-deoxyuridine; TFDU; 2'-Deoxy-5-(trifluoromethyl)uridine; NSC529182; F3T; F3TDR; TRIFLUOROTHYMIDINE; Trifluoromethyldeoxyuridine.
show more » |
DrugBank
Identification
| Name: | Trifluridine |
|---|---|
| Name (isomeric): | DB00432 |
| Drug Type: | small molecule |
| Description: | An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557) |
| Brand: | TFDU, Trifluridine [USAN:INN], Trifluridinum [INN-Latin], Virophta, F3DThd, F3TDR, Fluridine, Viroptic, Trifluridina [INN-Spanish], F3T, Trifluoromethyldeoxyuridine, trifluorothymine deoxyriboside, Trifluorothymidine, TFT |
| Category: | Antimetabolites, Antiviral Agents |
| CAS number: | 70-00-8 |
Pharmacology
| Indication: | Ophthalmic solution for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. |
|---|---|
| Pharmacology: |
Trifluridine is a fluorinated pyrimidine nucleoside with in vitro and in vivo activity against herpes simplex virus, types 1 and 2 and vacciniavirus. Some strains of adenovirus are also inhibited in vitro. Trifluridine is also effective in the treatment of epithelial keratitis that has not responded clinically to the topical administration of idoxu...
show more » |
| Mechanism of Action: |
The mechanism of action of trifluridine has not been fully determined, but appears to involve the inhibition of viral replication. Trifluridine does this by incorporating into viral DNA during replication, which leads to the formation of defective proteins and an increased mutation rate. This drug also reversibly inhibits thymidylate synthetase, an...
show more » |
| Absorption: | Systemic absorption of trifluridine following therapeutic dosing with trifluridine ophthalmic appears to be negligible. |
| Biotransformation: | One major metabolite, 5-carboxy-2'-deoxyuridine found on the endothelial side of the cornea, indicating localized metabolism. |
| Half Life: | Approximately 12 to 18 minutes following ophthalmic administration. |
| Toxicity: | Overdosage by ocular instillation is unlikely because any excess solution should be quickly expelled from the conjunctival sac. Acute overdosage by accidental oral ingestion has not occurred. However, should such ingestion occur, the 75 mg dosage of trifluridine in a 7.5 mL bottle of trifluridine is not likely to produce adverse effects. Single intravenous doses of 1.5 to 30 mg/kg/day in children and adults with neoplastic disease produce reversible bone marrow depression as the only potentially serious toxic effect and only after three to five courses of therapy. The acute oral LD50 in the mouse and rat was 4379 mg/kg or higher. |
| Affected organisms: | Human Herpes Virus |
Targets
Enzymes
Transporters
